SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Squibb Highlights Hematology Programs at ASH 2026

The company said its CELMoD programs are advancing across multiple myeloma and lymphoma, with Phase 3 readouts for ZENBEXUS. The body is truncated.

BMY

Related stories